Amanta Healthcare Q2 FY27: revenue up 17.3% YoY, SteriPort Line 3 commissioned
Q2 FY27 revenue ₹83.13 Cr, up 17.3% YoY; EBITDA ₹17.95 Cr at 21.6% margin; PAT ₹4.86Cr at a 6% margin.
By ScoutQuest · · 1 min read
- Q2 FY27 Revenue
- ₹83.13 Cr, up 17.3% YoY
- Q2 FY27 EBITDA
- ₹17.95 Cr at 21.6% margin
- Q2 FY27 PAT
- ₹4.86 Cr at a 6% margin
- Period
- Q2 FY27
- Positioning
- Amanta presents itself as a built-to-scale sterile formulations maker: a 66,852 sq mts Gujarat plant, 6 therapeutic segments, 320+ domestic distributors and exports to 27 countries, with 68% of revenue from India and 32% from exports.
📈 Q2 FY27 revenue was ₹83.13 Cr, up 17.3% year on year, with EBITDA of ₹17.95 Cr at a 21.6% margin and PAT of ₹4.86Cr at a 6% margin. The P&L prints Q2 FY27 PAT of ₹5 cr against ₹1 cr a year earlier, a swing helped by ₹3 cr of exceptional items booked in Q2 FY26 and none this quarter; H1 FY27 revenue was ₹151.94 Cr with PAT of ₹8.17 Cr.
📉 For the full year FY26 the company reports revenue of ₹288 cr against ₹275 cr in FY25, EBITDA of ₹63 cr versus ₹61 cr and PAT of ₹15 cr versus ₹11 cr, with ₹3 cr of exceptional items booked in FY26; FY23 PAT was a loss of ₹(2) cr.
🏭 On capacity, the company says SteriPort Line 3 was commissioned in the first week of September 2026, lifting SteriPort capacity 75% from 6.6 Cr to 11.6 Cr bottles; it expects ~₹60 Cr of revenue from the line in FY27 and ₹110–120 Cr a year at optimal utilisation. SVP capacity is to rise from 20.9 Cr to 31.7 Cr units during Q1 of FY28, and the deck cites current utilisation of 96%.
💰 Management states a two-year aim of 20%+ revenue CAGR and 25%+ EBITDA margin across three pillars — market depth, manufacturing and efficiency — and cites ~₹9 Cr of annual power savings from 10.8 MW captive solar plus debt-to-equity down from 3.5x in FY23 to ~1.1x in FY26; the FY26 balance sheet still shows non-current borrowings up to ₹162 cr from ₹132 cr.
Also from Amanta Healthcare
Amanta Healthcare posts audio recording of November 4, 2026 post results conference call on website
4 Nov 2026
CRISIL monitoring report: no deviation in use of IPO proceeds in September 2026 quarter
4 Nov 2026
Amanta Healthcare commissions SteriPort Line 3, SteriPort capacity up 75% to 11.6 crore bottles
4 Nov 2026
More numbers
- Revenue, Q2 FY27₹83.13 Cr
- EBITDA, Q2 FY27₹17.95 Cr
- PAT, Q2 FY27₹4.86Cr
- EBITDA margin, Q2 FY2721.6%
- Revenue, H1 FY27₹151.94 Cr
- PAT, H1 FY27₹8.17 Cr
- Revenue, FY26288 (Rs. in crs)
- PAT, FY2615 (Rs. in crs)
- SteriPort capacity increase75%
- Current capacity utilisation96%
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.